• Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel

Immunicum is listed on NASDAQ Stockholm under the ticker IMMU

About us

Developing innovative cancer immunotherapies

Immunicum is advancing a novel cell-based approach to target solid tumors.

Learn more
About